News|Articles|May 1, 2025
FDA Activity Recap: April 2025 Features Major Approval in RDEB, Multiple Breakthrough Therapy Designations, and More
Author(s)Noah Stansfield
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
Advertisement
Advertisement
Last month, April 2025, the CGTLive® team was diligently tracking the FDA's activities related to the development of cell and gene therapies for the treatment of rare, complex, and otherwise challenging diseases and disorders.
Advertisement
Advertisement